BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/28/2015 5:05:00 PM | Browse: 1252 | Download: 2753
Publication Name World Journal of Gastroenterology
Manuscript ID 17927
Country China
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Basic Study
Article Title Carvedilol may attenuate liver cirrhosis by inhibiting angiogenesis through the VEGF-Src-ERK signaling pathway
Manuscript Source Unsolicited Manuscript
All Author List Qian Ding, Xiang-Guo Tian, Yan Li, Qi-Zhi Wang and Chun-Qing Zhang
Funding Agency and Grant Number
Funding Agency Grant Number
National Natural Science Foundation of China 81370590
Corresponding Author Chun-Qing Zhang, PhD, Department of Gastroenterology, Provincial Hospital Affiliated to Shandong University, 324 Jingwu Weiqi Road, Jinan 250021, Shandong Province, China. zhchqing@medmail.com.cn
Key Words Carvedilol; Adrenergic β-antagonists; Angiogenesis; Liver cirrhosis; Drug utilization
Core Tip Carvedilol has been used for the treatment of portal hypertension for many years. In this study, carvedilol directly inhibited the proliferation and tube formation of cultured human umbilical vascular endothelial cells. Moreover, this study is the first to investigate the mechanism of the anti-angiogenic effect of carvedilol, which functions by inhibiting vascular endothelial growth factor-induced mitogen-activated protein kinase signaling pathways. These novel activities of carvedilol provide insight into the anti-angiogenic mechanisms involved, and highlight its potential therapeutic application against angiogenesis-dependent liver fibrosis.
Publish Date 2015-08-28 17:04
Citation Ding Q, Tian XG, Li Y, Wang QZ, Zhang CQ. Carvedilol may attenuate liver cirrhosis by inhibiting angiogenesis through the VEGF-Src-ERK signaling pathway. World J Gastroenterol 2015; 21(32): 9566-9576
URL http://www.wjgnet.com/1007-9327/full/v21/i32/9566.htm
DOI http://dx.doi.org/10.3748/wjg.v21.i32.9566
Full Article (PDF) WJG-21-9566.pdf
Full Article (Word) WJG-21-9566.doc